Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion previously received EMA approval for Remsima™ which is the world’s first biosimilar mAb to receive approval from a regulatory agency in a developed country. For more information, please visit http://www.celltrion.com/EN
Location: South Korea, Incheon
Employees: 1001-5000
Phone: +82 32-850-5000
Founded date: 2002
Investors 2
| Date | Name | Website |
| - | Temasek Ho... | temasek.co... |
| - | SJL Partne... | sjlpartner... |
Mentions in press and media 16
| Date | Title | Description |
| 31.10.2024 | ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs) | Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market The availability of ZYMFENTRA will support greater patient access and... |
| 30.08.2024 | /DISREGARD RELEASE: Celltrion USA/ | We are advised by Celltrion USA that journalists and other readers should disregard the news release, Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-... |
| 29.08.2024 | A New Era in Treatment: Celltrion USA's ZYMFENTRA® Partnership with Cigna and Express Scripts | In the ever-evolving landscape of healthcare, partnerships can pave the way for innovation and accessibility. Celltrion USA has recently made headlines by teaming up with Cigna Healthcare and Express Scripts. This collaboration aims to broa... |
| 29.08.2024 | Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit form... | JERSEY CITY, N.J., Aug. 29, 2024 /PRNewswire/ -- Celltrion USA announced today that it has signed an agreement with Cigna Healthcare, the health benefits provider of the Cigna Group and Express Scripts, the pharmacy benefits services busine... |
| 28.08.2024 | Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit form... | JERSEY CITY, N.J., Aug. 28, 2024 /PRNewswire/ -- Celltrion USA announced today that it has signed an agreement with Cigna Healthcare, the health benefits provider of the Cigna Group and Express Scripts, the pharmacy benefits services busine... |
| 13.08.2024 | Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program | Adalimumab-aaty was first approved by the Food and Drug Administration on May 23, 2023 and became commercially available among key distributors across the U.S. on July 2, 2023 Adalimumab-aaty's inclusion creates greater accessibility to tre... |
| 12.08.2024 | Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program | Adalimumab-aaty was first approved by the Food and Drug Administration on May 23, 2023 and became commercially available among key distributors across the U.S. on July 2, 2023 Adalimumab-aaty's inclusion creates greater accessibility to tre... |
| 06.07.2024 | 14 Celltrion Legacy products acquired by CBC-Backed Hasten Biopharmaceutical | The South Korean biopharmaceutical company Celltrion has successfully sold the asset rights to 14 branded products for use across Pan-Asia countries and regions to Hasten Biopharmaceutical (Hasten), an innovative biopharmaceutical company. ... |
| 10.05.2024 | Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost | Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients JERSEY CITY, N.J., May 10, 2024 /PRNewswire/... |
| 09.05.2024 | Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost | Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ ... |
Show more